A detailed history of Amalgamated Bank transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Amalgamated Bank holds 607 shares of MDGL stock, worth $131,719. This represents 0.0% of its overall portfolio holdings.

Number of Shares
607
Previous 505 20.2%
Holding current value
$131,719
Previous $135,000 25.93%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

BUY
$193.33 - $291.99 $19,719 - $29,782
102 Added 20.2%
607 $170,000
Q1 2024

Apr 23, 2024

SELL
$171.37 - $283.23 $276,591 - $457,133
-1,614 Reduced 76.17%
505 $135,000
Q4 2023

Feb 06, 2024

BUY
$120.4 - $237.13 $6,862 - $13,516
57 Added 2.76%
2,119 $490,000
Q3 2023

Nov 08, 2023

BUY
$146.04 - $225.78 $4,235 - $6,547
29 Added 1.43%
2,062 $301,000
Q2 2023

Aug 11, 2023

BUY
$203.88 - $312.0 $46,688 - $71,448
229 Added 12.69%
2,033 $469,000
Q1 2023

May 02, 2023

SELL
$231.06 - $307.08 $67,469 - $89,667
-292 Reduced 13.93%
1,804 $437,000
Q4 2022

Feb 10, 2023

BUY
$58.39 - $296.54 $2,744 - $13,937
47 Added 2.29%
2,096 $608,000
Q3 2022

Nov 09, 2022

BUY
$60.57 - $79.51 $1,817 - $2,385
30 Added 1.49%
2,049 $133,000
Q2 2022

Aug 15, 2022

BUY
$58.04 - $100.2 $5,804 - $10,020
100 Added 5.21%
2,019 $145,000
Q1 2022

Jun 30, 2022

BUY
$55.89 - $101.89 $107,252 - $195,526
1,919 New
1,919 $188,000
Q3 2021

Oct 29, 2021

SELL
$78.35 - $105.02 $168,060 - $225,267
-2,145 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$97.2 - $137.59 $208,494 - $295,130
2,145 New
2,145 $209,000
Q3 2018

Nov 14, 2018

SELL
$207.3 - $300.31 $184,082 - $266,675
-888 Closed
0 $0
Q2 2018

Jul 18, 2018

BUY
$101.55 - $313.9 $90,176 - $278,743
888 New
888 $248,000

Others Institutions Holding MDGL

About MADRIGAL PHARMACEUTICALS, INC.


  • Ticker MDGL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 17,103,400
  • Market Cap $3.71B
  • Description
  • Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...
More about MDGL
Track This Portfolio

Track Amalgamated Bank Portfolio

Follow Amalgamated Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Amalgamated Bank, based on Form 13F filings with the SEC.

News

Stay updated on Amalgamated Bank with notifications on news.